What should I look for in ARA-290 sourcing and quality?

Acceptable ARA-290 certificates of analysis specify: lot-specific (not template) issuance, HPLC purity ≥98%, mass spec confirmation matching 1257 Da, endotoxin testing for injectable routes, and third-party accredited laboratory issuance. Template COAs, missing endotoxin data, or vendor-internal labs are red flags. Pharmaceutical-grade compounded material is the lowest-risk supply path where accessible.

How long until I see results from ARA-290?

Acute effects from ARA-290 appear within hours of dosing for receptor-level changes. anabolic and recovery endpoints accumulate across 4–8 weeks; the typical 8–12 week cycle is calibrated to allow the full response window. Single-week evaluations consistently underestimate the response trajectory.

Is ARA-290 safe during pregnancy or breastfeeding?

ARA-290, like most non-approved peptide therapeutics, does not have safety data supporting use during pregnancy or lactation. The default position is contraindication during pregnancy, lactation, and active conception, with discontinuation at least 2–3 cycles before planned conception. Approved indications (where they exist) may have specific guidance — verify with the prescribing physician.

What is the evidence base for ARA-290?

ARA-290's evidence base sits at multiple phase ii human trials. The references on this page summarise 2 primary publications supporting the principal mechanism and applications. Where Phase II or Phase III human data exists for related indications, it is cited; where evidence is preclinical or limited to small case series, that is noted. The body composition / training interpretation respects the actual evidence tier rather than over-stating mechanistic plausibility.

Home/ Compounds/ ARA-290

ARA-290

Body Composition

For the body-composition and physique community, ARA-290 is run inside a training-driven framework where the compound supports rather than substitutes for stimulus and nutrition. Selectively activates the innate repair receptor (β-common-receptor / EPOR heteromer) on injured tissue Reduces inflammatory cytokine release and supports nerve and tissue repair. Critically, it does not bind the homodimeric EPOR responsible for erythropoiesis.. The ~2 min plasma; long tissue effect pharmacokinetic profile determines training-day versus rest-day dosing, while the subq administration shapes injection-site rotation and protocol planning.

Body Composition / Training Applications

StrengthLean MassTraining PerformanceMuscle EnduranceInjury Recovery

Key Takeaways

Body composition lens: response to ARA-290 is proportional to training stimulus and nutritional adequacy.
Mechanism: Selectively activates the innate repair receptor (β-common-receptor / EPOR heteromer) on injured tissue.
Body composition dose: 4 mg 1x daily subq via subq; effects visible at week 4-8 with adequate training and protein.
Cycle structure: 8-12 weeks on, 4 weeks off; training-day or daily dosing depending on half-life.
Performance stack partners: IGF-1 LR3, CJC-1295 + Ipamorelin Blend, TB-500.

Body Composition / Training Mechanism

Selectively activates the innate repair receptor (β-common-receptor / EPOR heteromer) on injured tissue. Reduces inflammatory cytokine release and supports nerve and tissue repair. Critically, it does not bind the homodimeric EPOR responsible for erythropoiesis. Body composition relevance of this mechanism depends on which dimension of the anabolic cascade ARA-290 engages: direct GH/IGF-axis activation, recovery-and-connective-tissue effects, or training-adjacent (sleep, inflammation) layers. The subsections below cover anabolic substrate, recovery window, training-day dosing, and hyperplasia versus hypertrophy.

Anabolic substrate and protein synthesis

ARA-290's relevance to body composition depends on where in the anabolic cascade it acts. It acts on adjacent rather than directly anabolic pathways, but the contribution to recovery, connective tissue, and inflammatory tone produces measurable body-composition effects in trained users. The downstream effect on body composition is dose- and training-dependent.

Training-day versus rest-day dosing

Many peptides in this category respond better to training-day-only versus rest-day-included dosing. ARA-290 with a ~2 min plasma; long tissue effect half-life of ~2 min plasma; long tissue effect is short-lived enough that timing relative to training sessions matters. The practical dosing schedule reflects this.

Hyperplasia and structural adaptation

Where ARA-290 demonstrates effects on fibre count rather than fibre size — hyperplasia rather than hypertrophy — the structural adaptation matters more than the acute anabolic signal. Most peptides in this category contribute to the hypertrophic rather than hyperplastic adaptation, with the magnitude depending on training stimulus.

Body Composition / Training Applications

Workout Recovery

The body composition community converges on ARA-290 for workout recovery with reported best-fit cycles of 8–12 weeks. Off-cycle of 4 weeks is standard. Stacking with complementary peptides on different pathways is the typical pattern for advanced users.

Muscle Endurance

For muscle endurance, ARA-290 integrates with training programming on a per-session and per-cycle basis. Training-day dosing produces stronger acute effect; rest-day inclusion supports sustained baseline. The protocol pattern reflects training intensity and recovery demand.

Lean Mass

Lean Mass responds to ARA-290 with effect sizes proportional to training stimulus and nutritional adequacy. Users running aggressive caloric deficits see reduced response; users in surplus with adequate protein see proportionally larger response. Programming the inputs is half the protocol.

Recovery

The body composition community converges on ARA-290 for recovery with reported best-fit cycles of 8–12 weeks. Off-cycle of 4 weeks is standard. Stacking with complementary peptides on different pathways is the typical pattern for advanced users.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	4 mg	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	2 mg	4–6 weeks initial cycle
Body Composition focus	SubQ	4 mg	1x daily SubQ
Maintenance phase	SubQ	3 mg	Ongoing with periodic pauses

Dose timing for ARA-290 is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

ARA-290 stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from performance coaches and athletes.

ARA-290 + IGF-1 LR3: Binds the IGF-1 receptor with full agonist activity. Pairs naturally with ARA-290's mechanism in body composition / training protocols.
ARA-290 + CJC-1295 + Ipamorelin Blend: CJC-1295 stimulates the GHRH receptor; ipamorelin stimulates the ghrelin/GHSR receptor. Pairs naturally with ARA-290's mechanism in body composition / training protocols.
ARA-290 + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with ARA-290's mechanism in body composition / training protocols.
ARA-290 + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with ARA-290's mechanism in body composition / training protocols.

Safety & Regulatory Status

WADA: Not specifically listed (EPO analogues require care) FDA: Unapproved (Phase II/III in sarcoidosis & neuropathy) Research: Multiple Phase II human trials

Excellent tolerability in published trials. Does not raise hemoglobin. Watch for rare injection site reactions.

Lens-specific safety considerations for body composition / training use of ARA-290: Excellent tolerability in published trials. Does not raise hemoglobin. Watch for rare injection site reactions. Additional body composition / training monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss

PMID 30760272

Supporting

Cibinetide (ARA 290) in diabetic neuropathy

PMID 27659024

ARA-290 vs Related Peptides

Compound	Profile	Onset	Best For
ARA-290	EPO-derived tissue-protective peptide	~2 min plasma; long tissue effect	Body Composition
IGF-1 LR3	Modified insulin-like growth factor 1	~20-30 hr (vs ~10 min for native IGF-1)	A modified IGF-1 with a 13-amino-acid N-terminal extension and Arg substitution that resists IGFBP binding — extending half-life from 10 minutes to roughly a day
Tesamorelin	Stabilised GHRH analogue	~30 min	An FDA-approved long-chain GHRH analogue used for HIV-associated lipodystrophy and notable for its consistent effect on visceral adipose reduction
Ipamorelin	Selective GHRP / ghrelin mimetic	~2 hr	The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite

Frequently Asked Questions

Should I cycle ARA-290?

Standard cycle structure for body composition use is 8–12 weeks on, 4 weeks off. Continuous indefinite use is not advised for most compounds in this class; the off-period preserves dose response and reduces cumulative downregulation. Cycle stacking with complementary peptides is common in advanced protocols.

Can I use ARA-290 alongside creatine, protein, and standard supplements?

Yes — peptide protocols are fully compatible with the standard supplement stack. Creatine, protein powder, beta-alanine, citrulline, and the like operate on entirely separate mechanisms and are additive. Pre-workout stimulants and high-caffeine intake are also compatible.

How does ARA-290 compare to AAS for body composition?

Peptide therapeutics including ARA-290 produce more modest body composition shifts than anabolic-androgenic steroids and operate on different mechanisms with substantially different side-effect profiles. The compound is most-appropriate for users prioritising long-term sustainability and clean blood work over maximum acute mass.

Will ARA-290 affect my training performance?

Most commonly via faster recovery between sessions, which permits higher training frequency and intensity. Acute performance-enhancing effects in a single session are not the typical profile. Users typically need to upregulate nutrition and adjust programming to take advantage of the increased recovery capacity.

How should ARA-290 be stored and reconstituted?

Lyophilised ARA-290 stores at −20°C for 18–24 months. After reconstitution with bacteriostatic water, the solution holds at 4°C for 14–28 days. Avoid freeze-thaw cycles of reconstituted material. Travel with cold packs in insulated containers; avoid prolonged exposure above 25°C. The standard reconstitution concentration is 1–2 mg/mL depending on the vial size.

Will ARA-290 actually increase lean mass?

ARA-290's effect on body composition depends on which dimension of the anabolic cascade it engages. Direct anabolic pathway engagement is not the principal mechanism, but contributions to recovery, connective tissue, and inflammatory tone produce measurable body-composition shifts in trained users. Effect size is proportional to training stimulus and nutritional adequacy.

Clinical Protocol

Start a ARA-290 Protocol

Alukard provides physician-supervised body composition protocols with GMP-certified ARA-290 and GMP-certified compounds and training-aware dosing guidance.

Get Protocol

Quick Facts

Molecular weight: 1257 Da
Sequence length: 11 aa
Half-life: ~2 min plasma; long tissue effect
WADA: Not specifically listed (EPO analogues require care)
FDA: Unapproved (Phase II/III in sarcoidosis & neuropathy)
Research: Multiple Phase II human trials

Stack Partners

IGF-1 LR3

CJC-1295 + Ipamorelin Blend

TB-500

BPC-157

Tesamorelin + Ipamorelin Blend

Research Note

All body composition / training applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for ARA-290 unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised body composition protocols

Start Your Body Composition / Training Protocol for ARA-290

Alukard provides physician-supervised body composition protocols with GMP-certified compounds and training-aware dosing guidance.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised